Curanex Pharmaceuticals Common Stock

CURX | NASDAQ

$5.29

+$0.35 (+7.09%)

At close: Oct 30, 2026, 3:59 PM ET

$5.10

-$0.19 (-3.63%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Fiscal Year Period Ending	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022
Revenue	n/a	n/a	n/a	26K
Cost of Revenue	n/a	n/a	n/a	21.57K
Gross Profit	n/a	n/a	n/a	4.43K
Operating Income	-4.24M	-365.06K	-19.3K	-20.23K
Interest Income	n/a	n/a	n/a	n/a
Pretax Income	-4.23M	-361.51K	-19.2K	-20.23K
Net Income	-4.23M	-361.51K	-19.2K	-20.23K
Selling & General & Admin	1.25M	290.39K	19.3K	24.66K
Research & Development	2.99M	n/a	n/a	n/a
Other Expenses	n/a	74.68K	n/a	n/a
Operating Expenses	4.24M	365.06K	19.3K	24.66K
Interest Expense	8.54K	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a
Cost & Expenses	4.24M	365.06K	19.3K	46.23K
Income Tax Expense	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	1.42M	1.39M	1.39M	1.39M
Shares Outstanding (Diluted)	1.42M	1.39M	1.39M	1.39M
EPS (Basic)	-2.98	-0.26	-0.01	-0.01
EPS (Diluted)	-2.98	-0.26	-0.01	-0.01
EBITDA	-4.22M	-290.39K	-17.48K	925
EBIT	-4.22M	-290.39K	-19.3K	-20.23K
Depreciation & Amortization	n/a	n/a	1.82K	21.16K